Books by Subject
- 2015 SpringerMicaela Morelli, Nicola Simola, Jadwiga Wardas, editors.
- 2014 SpringerEmilio Sacchetti, Antonio Vita, Alberto Siracusano, Wolfgang Fleischhacker.Poor adherence to therapy is one of the main obstacles to treatment effectiveness in schizophrenia. It is the main determinant of relapse, hospitalization, symptom persistence, and poor psychosocial functioning and outcome. Adherence to treatment is affected by various factors related to the disease characteristics, to the patient him- or herself, to the treatment, and to the therapeutic relationship. Some of these factors are modifiable, and both pharmacological and non-pharmacological strategies have been developed for this purpose.This book addresses the different aspects of adherence to treatment in schizophrenia and related disorders in a systematic but easy-to-use manual format. Chapters focus on a full range of issues, including pharmacological and non-pharmacological strategies to enhance adherence and continuity of care, relevant psychological factors, the importance of the patient-doctor relationship, and the need for an alliance with other care-givers. Adherence to Antipsychotics in Schizophrenia will be an invaluable asset for all who are involved in the care of patients with schizophrenia.
- 2013 SpringerJ.J. Sandra Kooij.1. Introduction -- 2. Diagnostic assessment -- 3. Diagnostic instruments -- 4. Treatment -- 5. Treatment: coaching adults with ADHD -- 6. Setup and organization of a specialist department.
- 2009 PsychiatryOnlineedited by Alan F. Schatzberg and Charles B. Nemeroff.
- 2012 Future Mededitor, Dan J. Stein.Antidepressants : past, present and future / Dan J. Stein -- Selective-serotonin reuptake inhibitors / Luo L. Wang & Raymond W. Lam -- Serotonin reuptake and receptor blockers / Michael Van Ameringen, Beth Patterson & Elizabeth Lee -- Serotonin noradrenaline reuptake inhibitors / Michel Bourin -- Noradrenaline dopamine-reuptake inhibitors / Peter Silverstone -- Noradrenergic and specific serotonergic antidepressants / Emma Heck & Glenda MacQueen -- Melatonin receptor agonists/5-HT2C antagonists / Sidney H. Kennedy & Sakina J. Rizvi -- Glutamatergic antidepressants / Harish Kalra, Olivia Dean, Seetal Dodd & Michael Berk -- Which therapy for which patient? / Tracy L. Greer, Benji T. Kurian & Madhukar H. Trivedi -- Index.
- 2013 SpringerP.N. Patsalos.Antiepileptic Drug Interactions: A Clinical Guide, Second Edition provides a pocket-sized, systematic description of the most clinically relevant drug interactions that occur between AEDs and also between AEDs and non-AEDs. AEDs are presented alphabetically and by drug class in three sections for easy access: Drug interactions between AEDs; Drug interactions between AEDs and non-AEDs: Interactions affecting AEDs; and Drug interactions between AEDs and non-AEDs: Interactions affected by AEDs. Antiepileptic Drug Interactions: A Clinical Guide, Second Edition should help physicians make more rational choices when polytherapy regimens are indicated and should be of interest to all who treat patients with epilepsy: neurologists and neurosurgeons, trainees at all levels, general practitioners and epilepsy nurse specialists.
- 2016 SpringerMichael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors.Section 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents -- 1. Pharmacokinetic Properties -- 2. Pharmacodynamic Properties -- 3. PET Scan and Other Biomarkers -- 4. Population Pharmacokinetics -- 5. Drug Transporters (esp. Blood Brain Barrier) -- 6. Pharmacogenomics -- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes -- 7. Antipsychotics -- oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics -- 8. Mood Stabilizers -- 9. Antidepressants -- tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants -- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 11. Opioid Analgesics -- 12. Stimulants and Other Non-Stimulants for ADHD -- 13. Cholinesterase Inhibitors and Other Antidementa Agents -- 14. Anti-Addiction Agents -- 15. Anesthetics -- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents -- 16. Antipsychotics -- 17. Mood Stabilizers -- 18. Antidepressants -- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 20. Opioid Analgesics -- 21. Stimulants and Other Non-Stimulants for ADHD -- 22. Cholinesterase Inhibitors and Other Antidementa Agents -- 23. Anti-Addiction Agents -- 24. Anesthetics.
- 2014 Cambridgeedited by Lenard Adler, Thomas J. Spencer, Timothy Wilens."Attention-Deficit Hyperactivity Disorder (ADHD) is a chronic neurobehavioral disorder characterized by persistent and often acute distractibility, hyperactivity, and impulsivity. It is a condition usually associated with children but in recent years the diagnosis of ADHD in adults has risen significantly. ADHD often coexists with a wide array of other psychiatric illnesses, including depression and bipolar disorder, thus complicating its assessment and management. In Attention-Deficit Hyperactivity Disorder in Adults and Children, a team of world renowned experts bring together the recent research in this area and cover the history, diagnosis, epidemiology, comorbidity, neuroimaging, and a full spectrum of clinical options for the management of ADHD. The wide ranging, detailed coverage in this text will be of interest to psychiatrists, psychologists, social workers, coaches, physicians, or anyone who wants to develop a deeper understanding of the etiology, characteristics, developmental process, diagnostics, and range of treatment modalities"--Provided by publisher.
- 20092009 ebraryEdward Shorter.Psychiatry today is a barren tundra, writes medical historian Edward Shorter, where drugs that don't work are used to treat diseases that don't exist. In this provocative volume, Shorter illuminates this dismal landscape, in a revealing account of why psychiatry is "losing ground" in the struggle to treat depression. Naturally, the book looks at such culprits as the pharmaceutical industry, which is not inclined to market drugs once the patent expires, leading to the endless introduction of new--but not necessarily better--drugs. But the heart of the book focuses on an unexpected villain: the FDA, the very agency charged with ensuring drug safety and effectiveness. Shorter describes how the FDA permits companies to test new products only against placebo. If you can beat sugar pills, you get your drug licensed, whether or not it is actually better than (or even as good as) current medications, thus sweeping from the shelves drugs that may be superior but have lost patent protection. The book also examines the FDA's early power struggles against the drug industry, an influence-grab that had little to do with science, and which left barbiturates, opiates, and amphetamines all underprescribed, despite the fact that under careful supervision they are better at treating depression, with fewer side effects, than the newer drugs in the Prozac family. Shorter also castigates academia, showing how two forms of depression, melancholia and nonmelancholia--"as different from each other as chalk and cheese"--Became squeezed into one dubious classification, major depression, which was essentially a political artifact born of academic infighting.
- 2013 SpringerPhilip J. Cowen, Trevor Sharp, Jennifer Y. F. Lau, editors.The book highlights important new research using current state-of-the-art approaches by prominent researchers in the field of depression. A broad range of topics is covered, beginning with a description of the phenotypic features of clinical depression, followed by chapters on the cellular and molecular basis, functional neuroimaging correlates and information-processing accounts. Finally, existing and novel treatment approaches are covered. In this way the volume brings together the key disciplines involved in the neurobiological understanding of depression to provide an update of the field and outlook to the future. Together, the volume chapters provide focused and critical reviews that span a broad range of topics suitable for both students and established investigators interested in the present state of depression research.
- 2011 SpringerJo C. Neill, Jayashri Kulkarni, editors.
- 2016 SpringerIvan D. Montoya, editor.Introduction -- PART I: Vaccines: Introduction -- Nicotine -- Cocaine -- Heroin -- Metamphetamine -- PART II: Monoclonal antibodies: Introduction -- Cocaine -- Metamphetamine -- PCP -- PART III: Enzymes: Introduction -- Butyrylcholinesterase -- Cocaine Esterase -- PART IV: New strategies to optimize the development of biologics: Adenovirus based vaccines -- Nanotechnology based vaccines -- Protein Nanoparticles -- DNA Scaffolded Vaccines -- Single Hapten Conjugate Therapeutic Vaccine -- Vaccine Adjuvants -- Laser Adjuvant -- Peptide Conjugates & Cytokine Adjuvants -- T. brucei: A Platform for Immunization -- Vaccines for SUDs and HIV infection -- New Monoclonal Antibodies -- Protein Engineered for Controlled Duration of Action -- PART V: Ethical aspects of biologics to treat SUDs.
- 2015 SpringerLois W. Choi-Kain, John G. Gunderson, editors.In Borderline Personality and Mood Disorders: Comorbidity and Controversy, a panel of distinguished experts reviews the last two decades of progress in scientific inquiry about the relationship between mood and personality disorders and the influence of this empirical data on our ways of conceptualizing and treating them. This comprehensive title opens with an introduction defining general trends both influencing the expansion of the mood disorder spectrum and undermining clinical recognition and focus on personality disorders. The overlaps and differences between MDD and BPD in phenomenology and biological markers are then reviewed, followed by a review of the overlaps and distinctions between more atypical mood disorder variants. Further chapters review the current state of thinking on the distinctions between bipolar disorder and BPD, with attention to problems of misdiagnosis and use of clinical vignettes to illustrate important distinguishing features. Two models explaining the relationship between mood, temperament, and personality are offered, followed by a review of the literature on risk factors and early signs of BPD and mood disorders in childhood through young adulthood as well as a review of the longitudinal studies on BPD and mood disorders. The last segment of the book includes three chapters on treatment. The book closes with a conclusion with a synthesis of the current status of thinking on the relationship between mood and borderline personality disorder. An invaluable contribution to the literature, Borderline Personality and Mood Disorders: Comorbidity and Controversy insightfully addresses the mood and personality disorders realms of psychiatry and outlines that it has moved away from contentious debate and toward the possibility of synthesis, providing increasing clarity on the relationship between mood and personality to inform improvements in clinical management of the convergence of these psychiatric domains in common practice.
- 2013 SpringerRoss J. Baldessarini.Use of psychotropic drugs has come to dominate clinical practice in psychiatry worldwide--perhaps owing largely to perceived simplicity, ease of use, and apparent efficiency, as well as apparent cost-effectiveness of such treatments. Nevertheless, medicinal treatments for patients with psychiatric disorders are but one component of comprehensive clinical care of complex human problems. Extensively updated since its second edition in 1985, Chemotherapy in Psychiatry, Third Edition, again addresses basic aspects of modern psychopharmacology and clinical applications of drugs used in the treatment of major psychiatric disorders, with major emphasis on psychotic, bipolar, and depressive disorders. The presentation covers descriptions of the main classes of psychotropic drugs, selected information concerning their known action mechanisms and metabolic disposition, and their clinical applications for acute illnesses and to prevent recurrences and long-term morbidity. Also covered are limitations and adverse effects of each type of agent, with emphasis on the fact that all psychotropic medicines have adverse effects that range from annoying to potentially lethal. Chemotherapy in Psychiatry, Third Edition, outlines the need to balance benefits and risks at the level of individual persons. Authoritative, and an important contribution to the literature, Chemotherapy in Psychiatry, Third Edition is an invaluable resource for physicians, scientists, trainees, and policymakers.
- 2007 OvidWayne Hugo Green.General principles of psychopharmacotherapy with children and adolescents -- Sympathomimetic amines and central nervous system stimulants -- First generation/typical antipsychotic drugs -- Second generation/atypical and other antipsychotic drugs -- Antidepressant drugs -- Mood stabilizers : lithium carbonate and antiepileptics -- Antianxiety drugs -- Other drugs.Also available: Print – 2007
- 2010 ebraryeditors, Marc Hertzman, Lawrence Adler."This book comprises a series of critical reviews of the latest developments in clinical trials for psychopharmacologic drugs over the past decade. It evaluates key trials and their impact on management and treatment of specific disorders. Clearly written, the text provides immediate access to new developments across the spectrum of drug testing, written by the leaders in the field"--Provided by publisher.
- 2014 SpringerJoseph Sadek.The Clinicians Guide to ADHD combines the useful diagnostic and treatment approaches advocated in different guidelines with insights from other sources, including recent literature reviews and web resources. The aim is to provide clinicians with clear, concise, and reliable advice on how to approach this complex disorder. The guidelines referred to in compiling the book derive from authoritative sources in different regions of the world, including the United States, Canada, Australia, and Europe. After introductory discussion of epidemiology and etiology, guidance is provided on diagnosis in different age groups, differential diagnosis, assessment for potential comorbidities, and the issue of ADHD and driving. Advice is then given on the appropriate use of pharmacological and psychosocial treatment, the management of adverse events, and follow-up. A series of relevant scales, questionnaires, and websites are also included.
- 2012 SpringerGerhard Gross, Mark A. Geyer, editors."Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics...Our intention was to capture both the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We [prepared] two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume."--Publisher's description.
- 2015 Springer Protocolsedited by Gerald Thiel.Defining the functional equivalence of wild-type and chemically engineered G protein-coupled receptors / Elisa Alvarez-Curto and Graeme Milligan -- Design and analysis of an arrestin-biased DREADD / Ken-ichiro Nakajima ... [et al.] -- Regulation of gene transcription following stimulation of Gαq-coupled designer receptors / Oliver G. Rössler and Gerald Thiel -- Chemogenetic deconstruction of feeding circuits / Michael Krashes -- Dissecting neuronal circuits involved in olfactory-mediated behaviors / Alexia Nunez-Parra ... [et al ] -- Use of DREADDs (Designer Receptors Exclusively Activated by Designer Receptors) in transgenic mouse behavioral models / Daniela Cassataro and Lucas Sjulson -- Pharmacogenetic dissection of neural mechanisms underlying the regulation of sleep-wakefulness using DREADDs / Michihiro Mieda and Takeshi Sakurai -- DREADD'ed addiction : using designer receptors to delineate neural circuits underlying drug-seeking behaviors / Sunila G. Nair, Denis Smirnov, and John F. Neumaier -- DREADDs in Drosophila melanogaster / Charles D. Nichols and Jaime Becnel.
- 2015 Springer Protocolsedited by Mario Tiberi.Genetic and epigenetic methods for analysis of the dopamine D2 receptor gene / Laura M. Fiori , Mireille Daigle , and Paul R. Albert -- Characterization of D1 dopamine receptor posttranscriptional regulation / Eldo V. Kuzhikandathil -- Computational approaches in the structure-function studies of dopamine receptors / Mayako Michino and Lei Shi -- Cell-free protein synthesis and purification of the dopamine D2 receptor / Dipannita Basu ... [et al.] -- Wnt ligand binding to and regulation of dopamine D2 receptors / Sehyoun Yoon , Mi-Hyun Choi , and Ja-Hyun Baik -- Regulation of pre- and postsynaptic protein phosphorylation by dopamine D2 receptors / Alessandra Bonito-Oliva, Giada Spigolon, and Gilberto Fisone -- Study of dopamine D1 receptor regulation by G protein-coupled receptor kinases using whole-cell phosphorylation and cross-linking methods / Keyvan Sedaghat ... [et al.] -- Ubiquitination of dopamine receptor studied by sequential double immunoprecipitation / Kamila Skieterska, Pieter Rondou, and Kathleen Van Craenenbroeck -- Dopamine receptors in the subthalamic nucleus : identification and localization of D5 receptors / Lionel Froux ... [et al.] -- MALDI mass spectrometry imaging of dopamine and PET D1 and D2 receptor ligands in rodent brain tissues / Richard J. A. Goodwin, Mohammadreza Shariatgorji, and Per E. Andren -- Positron emission tomography imaging of dopaminergic receptors in rats / Boguslaw Szczupak and Abraham Martín -- Transactivation of receptor tyrosine kinases by dopamine receptors / Jeff S. Kruk ... [et al.] -- Dopamine receptors in human embryonic stem cell differentiation / Glenn S. Belinsky ... [et al.] -- Calcium and phospholipase Cβ signaling through dopamine receptors / Lani S. Chun, R. Benjamin Free, and David R. Sibley -- Intracellular trafficking assays for dopamine D2-like receptors / Chengchun Min, Mei Zheng, and Kyeong-Man Kim -- Study of crosstalk between dopamine receptors and ion channels / Ping Su, Albert H. C. Wong, and Fang Liu -- Study of dopamine receptor and dopamine transporter networks in mice / Victor Gorgievski, Eleni T. Tzavara, and Bruno Giros -- Optogenetic regulation of dopamine receptor-expressing neurons / T. Chase Francis and Mary Kay Lobo -- Characterization of D3 dopamine receptor agonist-dependent tolerance property / Samantha R. Cote and Eldo V. Kuzhikandathil -- Dopamine D1 and D2 receptors in chronic mild stress : analysis of dynamic receptor changes in an animal model of depression using in situ hybridization and autoradiography / Dariusz Zurawek ... [et al.].
- 2014 SpringerVeena Kumari, Petr Bob, Nash N. Boutros, editors.Psychophysiology is an ever expanding field. The application of psychophysiological investigations to psychiatric disorders is likewise expanding and has in fact shed much light on some of the neural processes contributing to the development of psychiatric symptoms and/or their amelioration following treatment. The first part of this volume deals with a number of conditions where psychophysiological investigations have recently provided some insight into the pathophysiology of a particular manifestation (e.g., dissociation) or a disorder. Although this volume has a main focus on electrophysiological investigative modalities where neuroimaging was complimentary this added insight was included. The second part of the volume focuses on novel uses of psychophysiological measures, combining it with neuropsychology and imaging where possible, in the context of neuropsychiatric research and describes advanced analytical tools. Both basic and clinical investigators in this field should find the reviews and interpretations provided clear and informative. Clinicians will find this volume easy to assimilate. While direct clinical applications may be down the road, the insights provided should help the practicing clinicians to have firmer understanding of the complexity of the disorder they manage in everyday practice.
- 2010 Springeredited by Ian P. Stolerman.
- 2011 SpringerW. Wolfgang Fleischhacker, Ian P. Stolerman (eds.).Key Essays: Active Avoidance / Marie-Louise G. Wadenberg -- Aggressive Behavior: Clinical Aspects / Emil F. Coccaro, -- Aminergic Hypothesis for Schizophrenia / Hiroyuki Uchida and Shitij Kapur -- Animal Models for Psychiatric States / Paul Willner -- Antipsychotic Drugs / W. Wolfgang Fleischhacker -- Anti-Parkinson Drugs / Joseph H. Friedman -- Antipsychotic Medication: Future Prospects / Seiya Miyamoto -- Cognitive Behavioral Therapy for People with Schizophrenia / Gillian Haddock -- Cognitive Remediation in Schizophrenia Patients / Alice Medalia and Alice Saperstein -- Delayed Onset of Drug Effects / Stefan Leucht -- Delusional Disorder / Istvan Bitter -- Dissociative Anesthetics / Anthony Absalom and David Menon -- Family Based Approaches for Schizophrenia Patients / Andrea Fiorillo and Silvana Galderisi -- First-Generation Antipsychotics / Cyril Höschl -- Hallucinations / Eileen M. Joyce -- Hallucinogen / Abuse and Dependence / John H. Halpern, Pedro E. Huertas, Joji Suzuki, and Torsten Passie -- Neurotoxicity and Schizophrenia / Heleen B. M. Boos, H. D. Postma, and Wiepke Cahn -- Pediatric Schizophrenia / Christoph U. Correl -- Pharmacogenetics of Antipsychotic Drug Response in Schizophrenia / Eva J. Brandl and Daniel J. Müller -- Pharmacogenetics of Drug Side Effects and Safety / Anil K. Malhotra and Todd Lencz -- Postpsychotic Depressive Disorder of Schizophrenia / Samuel G. Siris -- Pre-psychotic States and Prodromal Symptoms / Patrick D. Mcgorry, Alison R. Yung -- Psychoeducation in the Management of Schizophrenia / Werner Kissing and Gabriele Pitschel-Walz -- Rating Scales and Diagnostic Schemata / David V. Sheehan and Kathy H. Sheehan -- Rehabilitation in Schizophrenia / Wulf Rössler and Andreas Marneros -- Schizophrenia / Alex Hofer -- Second and Third Generation Antipsychotics / Gary Remington.
- 2012 Cambridgeedited by Dan Stein, Bernard Lerer, Stephen Stahl.
- 2016 SpringerJanusz K. Rybakowski, Alessandro Serretti, editors.
- 2014 OvidWilliam M. Klykylo ... [et al].The ideal quick reference for the busy mental health clinician seeing younger patients, the Fifth Edition of Green's Child and Adolescent Clinical Psychopathology has been fully revised by a new team of authors active in clinical practice and resident education. A trusted reference in the field, Green's continues to provide practical and balanced information on the full range of medications used to treat mental health disorders in children and adolescents. ... NEW to the Fifth Edition: Increased focus on medication effects and cost-effectiveness. New information on cardiac function and risk factors in patients taking stimulants. Long-term suicide risks associated with SSRIs. Longer term outcomes of major depression treatment. Use of anticonvulsant medications in patients with bipolar disorder. Weight gain in patients taking antipsychotics.
- 2014 CambridgeD.G. Cunningham-Owens, Professor of Clinical Psychiatry, University of Edinburgh, Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh, UK.1. The origins of psychopharma -- 2. Some preliminaries -- 3. Acute dystonia -- 4. Parkinsonism -- 5. Akathisia -- 6. Tardive dyskinesia -- 7. Tardive and chronic dystonia -- 8. Special populations -- 9. The clinical examination -- 10. An overview of some standardised recording instruments -- 11. Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia? -- 12. And finally ... the salutary tale of 'atypicality' -- References -- Index.
- 2014 SpringerEdward S Friedman, Ian M Anderson ; with contributions from Danilo Arnone, Timothey Denko.Depression is a common mood disorder that affects approximately 10% of the global population at some point in their lives and can cause serious psychological, physical, and cognitive distress. Additionally, patients with depression are at a greater risk for cardiovascular disease, stroke, functional impairment, disability and all-cause mortality. Aside from the impact on the individual, this condition presents a very real economic burden, as depression is the most predominant mental health problem among working-age patients and the leading cause of lost work productivity. Despite advances in screening and treating depression in recent decades, a vast majority of patients with depression do not actively seek treatment and, of those that do, only a quarter have been found to receive adequate and effective interventions. Handbook of Depression, Second Edition is a concise review of assessment tools, available and emerging pharmacological and non-pharmacological treatment options, and consensus management guidelines that center on enhancing the clinician-patient relationship and improving patient quality of life. Cowritten by expert US- and UK-based authors, this handbook has an innovative global focus that consolidates current knowledge in a convenient, pocket-sized guide that is ideal for every day reference in a clinical setting.
- 2010 ScienceDirectedited by Christian P. Müller and Barry L. Jacobs.Section 1: Functional anatomy of the serotonergic system -- Evolution of serotonin : sunlight to suicide / Efrain C. Azmitia -- Genetic organisation of the serotonergic system / Ursula M. D'Souza and Ian W. Craig -- The neuronatomy of the serotonergic system / Jean-Pierre Hornung -- Ultrastructure of the serotonin innervation in mammalian central nervous system / Laurent Descarries, Mustapha Riad and Martin Parent -- Classification and signaling characteristics of 5-HT receptors / Joel Bockaert, Sylvie Claeysen, Aline Dumuis and Philippe Marin -- Distribution of 5-HT receptors in the central nervous system / Guadalupe Mengod, Roser Cort s, M. Teresa Vilar and Daniel Hoyer -- Measuring serotonin activity in vivo in the brains of animals and humans / Charles A Marsden -- Section 2: The neurophysiology of serotonin -- Activity of brain serotonergic neurons in relation to physiology and behavior / Barry L. Jacobs and Casimir A. Fornal -- Electrophysiology of serotonin receptors / Gerard J. Marek -- Tryptophane hydroxylase and serotonin synthesis regulation / Hiroyuki Hasegawa and Kazuhiro Nakamura -- The degradation of serotonin : role of MAO / Marco Bortolato, Kevin Chen and Jean C Shih -- Cellular effects of serotonin in the CNS / Rodrigo Andrade and Sheryl G. Beck -- Serotonergic feedback control / Trevor Sharp -- Tryptophan depletion and serotonin release : a critical reappraisal / Matthijs G.P. Feenstra and Geoffrey van der Plasse -- Serotonin interaction with other transmitter systems / Albert Adell, Anal a Bortolozzi, Llorenc D iaz-Mataix, Noem Santana, Pau Celada, and Francesc Artigas -- Serotonergic regulation of rhythmical activity of the brain, concentrating on the hippocampus / Robert P. Vertes -- 5-HT neurons and central CO 2 chemoreception / Carolin I. Dohle and George B. Richerson -- Section 3: Serotonin and behavioural control -- Serotonin and development / Patricia M. Whitaker-Azmitia -- Serotonin and basal sensory : motor control / Robert J. Carey -- Role of the serotonergic system in appetite and ingestion control / Michelle D. Lee and Peter G. Clifton -- Serotonin and sexual behavior / Lynda Uphouse and Jutatip Guptarak -- Serotonin in mood and emotion / Julie G. Hensler -- Serotonin and the neurobiology of anxious states / Christopher A. Lowry and Matthew W. Hale -- Role of Serotonin in Brain Reward and Regulation of Alcohol Drinking Behavior / W. J. McBride -- Role of central serotonin in impulsivity and compulsivity : Comparative studies in experimental animals and humans / TW Robbins & MJ Crockett -- Experimental studies on the role(s) of serotonin in learning and memory functions / Jean-Christophe Cassel -- Social behavior and serotonin / Elif Aysimi Duman and Turhan Canli -- Serotonin in pain and pain control / Claudia Sommer -- Section 4: Serotonin in disease conditions --The Impact of Stress on Serotonergic Neurotransmission / Astrid C.E. Linthorst and Johannes M.H.M. Reul -- Role for serotonin in depression / Gregory V. Carr and Irwin Lucki -- The role of serotonin in drug addiction / Christian P. M ller, Martin E. Pum, Gunter Schumann and Joseph P. Huston -- The serotonergic system in obsessive compulsive disorders / Addy van Dijk, Andre Klompmakers, and Damiaan Denys --The role of serotonin in attention-deficit hyperactivity disorder (ADHD) / Robert D. Oades -- Serotonin and schizophrenia / Boris B. Quednow, Mark A. Geyer, and Adam L. Halberstadt -- Serotonin and serotonin receptors in hallucinogen action / Adam L. Halberstadt and David E. Nichols -- The role of serotonin in cortical development : implications for Autism Spectrum Disorder [ASD] / Christine F. Hohmann and Mary E. Blue -- Serotonin in panic and anxiety disorders / Francisco Silveira Guimar es, H lio Zangrossi Jr., Cristina Marta Del Ben and Frederico Guilherme Graeff -- Serotonin and agression / Isabel M. Quadros, Aki Takahashi and Klaus A. Miczek -- Altered serotonin function in anorexia and bulimia nervosa / Vikas Duvvuri, Ursula F Bailer and Walter H Kaye -- Genetic, epigenetic, and environmental factors in serotonin associated disease conditions / Eva Friedel & Andreas Heinz -- The Behavioral Genetics of Serotonin : Relevance to Anxiety and Depression / Olivia F. O'Leary and John F. Cryan -- Functional pharmacogenetics of serotonin receptors in psychiatric drug action / Olga O. Yevtushenko, Gavin P. Reynolds.
- 2013 SpringerLeslie Citrome.Handbook of Treatment-resistant Schizophrenia is a concise review of treatment-resistant schizophrenias definition, measurement tools, adherence issues, substance abuse, optimal dosing, clinicianpatient relationships, and current management approaches. The book was originally commissioned with the intention of creating a comprehensive text focusing on treatment-resistant schizophrenia and its management. The book explores many aspects of the background and practice- and research-based evidence for treating this complex subset of schizophrenia, including psychopharmacological, somatic, and nonpharmacological treatment approaches. While exploring the various therapies for treatment-resistant schizophrenia, Dr Citrome also emphasizes the importance of building strong and trusting relationships between patients and their clinicians so the clinician can best manage their patients adherence and overall treatment.
- 2013 WileyMark Walker.What is living and what is dead in brave new world -- What do we mean by "happiness"? -- The elements of the good life : it is a very big list -- Wellbeing and virtue -- Happiness promotes perfection -- Happy pharmacology -- Arguments for happy-people-pills -- Ethical objections -- Happy-people-pills and public policy.
- Helping parents and teachers understand medications for behavioral and emotional problems : a resource book of medication information handouts. Fourth edition [4th ed.]2015 PsychiatryOnlineedited by Mina K. Dulcan, M.D., Rachel R. Ballard, M.D.Contributors -- Introduction for Clinicians to the Fourth Edition -- Selected Additional Reading for Health and Mental Health Professionals -- Published Resources for Parents and Teachers -- Information on the Internet -- Copyright, Citation, and Disclaimer -- Appendix 1: Medicines With FDA Indication for Attention-Deficit/Hyperactivity Disorder (ADHD) -- Appendix 2: Medicines Typically Used for Anxiety and Depression -- Appendix 3: Medicines Typically Used for Psychosis -- Appendix 4: Medicines Typically Used for Mood Stabilization or Reducing Aggression Drugs by Generic and Brand Names: Alprazolam (Xanax) -- Amitriptyline -- Amphetamine (Dexedrine, ProCentra, Zenzedi, Adderall, Vyvanse) -- Aripiprazole (Abilify) --Asenapine (Saphris) -- Atenolol (Tenormin) -- Atomoxetine (Strattera) -- Benzodiazepines Used for Sleep: Estazolam (ProSom), Flurazepam, Temazepam (Restoril), Triazolam (Halcion) -- Benztropine (Cogentin) -- Bupropion (Wellbutrin, Aplenzin, Forfivo) -- Buspirone -- Carbamazepine (Tegretol, Carbatrol, Epitol, Equetro, Tegretol XR) -- Chlorpromazine -- Citalopram (Celexa) -- Clomipramine (Anafranil) -- Clonazepam (Klonopin) -- Clonidine (Catapres, Catapres-TTS, Kapvay) -- Clozapine (Clozaril, FazaClo, Versacloz) -- Cyproheptadine -- Desipramine (Norpramin) -- Desmopressin Acetate (DDAVP, Stimate) -- Diazepam (Valium) -- Diphenhydramine (Benadryl) -- Duloxetine (Cymbalta) -- Escitalopram (Lexapro) -- Fluoxetine (Prozac, Symbyax) -- Fluphenazine -- Fluvoxamine (Luvox CR) -- Gabapentin (Neurontin, Gralise, Gralise Starter) -- Guanfacine (Tenex, Intuniv) -- Haloperidol (Haldol) -- Hydroxyzine (Vistaril) -- Hypnotics-Sleep Medications (Nonbenzodiazepines): Eszopiclone (Lunesta), Zaleplon (Sonata), Zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist) -- Iloperidone (Fanapt) -- Imipramine (Tofranil) -- Lamotrigine (Lamictal, Lamictal XR) -- Levomilnacipran (Fetzima) -- Lithium (Lithobid) -- L-methylfolate (Deplin) -- Lorazepam (Ativan) -- Loxapine (Loxitane, Adasuve) -- Lurasidone (Latuda) -- Melatonin -- Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet) -- Methylphenidate (Methylin, Ritalin, Metadate, Concerta, Daytrana, Quillivant, Focalin) -- Mirtazapine (Remeron) -- Modafinil (Provigil), Armodafinil (Nuvigil) -- N-acetylcysteine -- Nortriptyline (Pamelor) -- Olanzapine (Zyprexa, Symbyax) -- Omega-3 Fatty Acids (Epanova, Lovaza) -- Oxcarbazepine (Trileptal, Oxtellar XR) -- Paliperidone (Invega) -- Paroxetine (Paxil, Pexeva, Brisdelle, Paxil CR) -- Perphenazine -- Pimozide (Orap) -- Pindolol -- Prazosin (Minipress) -- Propranolol (Inderal) -- Quetiapine (Seroquel) -- Ramelteon (Rozerem) -- Risperidone (Risperdal) -- Sertraline (Zoloft) -- Thiothixene -- Topiramate (Topamax, Topiragen, Trokendi XR, Qudexy SR) -- Trazodone (Oleptro) -- Trifluoperazine -- Valproic Acid (Depakene, Stavzor), Divalproex (Depakote, Depakote ER, Depakote Sprinkles) -- Venlafaxine (Effexor), Desvenlafaxine (Pristiq, Khedezla) -- Vilazodone (Viibryd) -- Vortioxetine (Brintellix) -- Ziprasidone (Geodon).
- v. 2, <5>, 1989, <1995>edited by I. Hindmarch and P.D. Stonier.Status: Not Checked OutLane Catalog Record
- 2013 Kargervolume editors, A. Halaris, Maywood, Ill., B.E. Leonard, Galway.Basic aspects of the immunology of neuroinflammation / Wohleb, E.S.; Godbout, J.P. -- Stress and neuroinflammation / Grippo, A.J., Scotti, M.-A.L. -- Role of inflammation in depression : implications for phenomenology, pathophysiology and treatment / Raison, C.L., Miller, A.H. -- Virus infection as a cause of inflammation in psychiatric disorders / Bechter, K. -- Inflammation, neurotoxins and psychiatric disorders / Myint, A.-M. -- Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders / Song, C. -- The brain-gut axis : a target for treating stress-related disorders / Scott, L.V., Clarke, G., Dinan, T.G. -- The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs / Arolt, V., Ambrée, O. -- Inflammation as the cause of the metabolic syndrome in depression / Leonard, B.E. -- Glucocorticoids and inflammation : a double-headed sword in depression? / Horowitz, M.A. ... [et al.] -- Co-morbidity between cardiovascular pathology and depression : role of inflammation -- Halaris, A. -- Inflammatory and oxidative and nitrosative stress cascades as new drug targets in myalgic encephalomyelitis and chronic fatigue syndrome -- Maes, M. -- Peripheral inflammation and cognitive aging -- Lim, A., Krajina, K., Marsland, A.L. -- Inflammation in suicidality : implications for novel treatment options / Janelidze, S., Brundin, L.
- Isoquinolines and beta-carbolines as neurotoxins and neuroprotectants : new vistas In Parkinson's disease therapy2012 SpringerLucyna Antkiewicz-Michaluk, Hans Rommelspacher, editors.
- 2006Benjamin J. Sadock, Virginia A. Sadock, Norman Sussman.
- 2013 SpringerJoel Paris, James Phillips, editors.
- 2013 Springereditor, Eduard Vieta, Director of the Bipolar Disorders Program, Hospital Clinic, University of Barcelona, Spain."Managing Bipolar Disorder in Clinical Practice", Third Edition, is an up-to-date, concise practical handbook developed with the clinician in mind. Including the most recent clinical guidelines, including the British Association for Psychopharmacology (BAP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines, this handbook is intended to highlight every major aspect of this serious mental health disorder, including assessment, treatment, long-term management, and recent developments.
- 2011 SpringerEdward S Friedman and Ian M Anderson ; with contributions from Danilo Arnone, Timothey Denko.Classification, causes, and epidemiology. Different types of depression ; Causes of depression ; Epidemiology and natural history -- Depression in different types of patients. Depression in children ; Depression in elderly people ; Depression in women ; Depression in patients with comorbid medical conditions -- Diagnosis. Signs and symptoms of depression ; Differential diagnosis ; The patient examination and interview ; Laboratory tests for co-occurring illnesses -- Principles of therapy. Goals of treatment ; Treatment options ; Choice of treatment ; Practicalities of treatment ; Factors affecting response to treatment -- Medications. Selective serotonin reuptake inhibitors ; Serotonin and norepinephrine reuptake inhibitors ; Monoamine receptor antagonist drugs ; Norepinephrine reuptake inhibitors ; Dopamine reuptake inhibitors ; Tricyclic antidepressants ; Monoamine oxidase inhibitors ; Other drugs ; Specific adverse effects of antidepressants -- Other treatments. Psychotherapy for depression ; Combination psychotherapy and psychopharmacotherapy for depression ; Physical treatments ; Lifestyle and complementary therapies -- Management of treatment nonresponse. Assessment and principles of management ; Definitions: treatment nonresponse and treatment-resistant depression ; Medication strategies ; Psychological treatment strategies ; Physical treatment strategies -- Continuation and maintenance treatment. Goals of continuation/maintenance treatment ; Phases of treatment ; Medication ; Psychological treatments ; Physical treatments ; Risk factors for relapse and recurrence ; Longer-term treatment in practice.
- 2015 PsychiatryOnlineAlan F. Schatzberg, M.D., Kenneth t. Norris, Jr. Professor, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, Charles DeBattista, D.M.H., M.D., Professor of Psychiatry and Behavioral Sciences, Co-Director, Depression Research Clinic and Research Program, Director, Mood Disorders Center, Director, Medical Student Education in Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.General principles of psychopharmacological treatment -- Diagnosis and classification -- Antidepressants -- Antipsychotic drugs -- Mood stabilizers -- Antianxiety agents -- Hypnotics -- Stimulants and other fast-acting drugs -- Augmentation strategies for treatment-resistant disorders -- Emergency department treatment -- Pharmacotherapy for substance use disorders -- Pharmacotherapy in special situations.
- 2003 Ovid[edited by] Richard I. Shader.Also available: Print – 2003
- 2016 ClinicalKeyeditors, Theodore A. Stern, Maurizio Fava, Timothy E. Wilens, Jerrold F. Rosenbaum.Put today's best approaches to work for your patients with this practical guide to cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions. Edited by Drs. Theodore A. Stern, Maurizio Fava, Timothy E. Wilens, and Jerrold F. Rosenbaum, and comprised of key chapters from the second edition of Stern et al.'s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this user-friendly resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psycholog.
- 2014 SpringerSrinivasan Venkataramanujam, Amnon Brzezinski, Sukru Oter, Samuel D. Shillcutt, editors.The book aims to cover basic physiologic functions of melatonin, and its therapeutic applications in humans for a variety of clinically relevant disorders. This bookcontains chapters on the recent aspects of melatonin physiology, its receptors and their role in mitochondrial function, its immunomodulatory role and importance in seasonal dependent diseases, role in human reproduction, role in sleep, circadian rhythm and sleep disorders, role in neurologic disorders such as Parkinsons disease, Alzheimers disease. Additionally, melatonins therapeutic use in neurobehavioral disorders in children, migraine and tension headache is also covered in this book. Melatonins antioxidant role in Duchennes muscular dystrophy and in glaucoma have also been discussed in short chapters. Two major melatonin agonists, ramelteon and agomelatine are discussed extensively on their current clinical application and ongoing research. Two chapters on agomelatonin and its role in mood disorders, particularly depressive disorders, are an important feature of this book. The chapters are written by experts from the global academia recognized for their original research and published work in the field of melatonin science.
- 2009 Kargervolume editors, J. Thakore, B.E. Leonard.Metabolic syndrome and schizophrenia : is inflammation the cause? / Leonard, B.E. -- Insulin resistance in bipolar women : effects of mood-stabilizing drugs / Vemuri, M. ... [et al.] -- Obesity and mental illness / Citrome, L.; Vreeland, B. -- Glucose abnormalities in schizophrenia, bipolar and major depressive disorders / Bushe, C. -- Screening for diabetes and cardiovascular risk factors in people with serious mental illness / Holt, R.I.G.; Peveler, R.C. -- Stress axis dysfunction : a common finding in schizophrenia and the metabolic syndrome? / Afzal, A.; Thakore, J. -- Metabolic syndrome in psychiatric inpatients treated for depression / Goethe, J.W.; Szarek, B.L.; Caley, C.F. -- Hyperprolactinaemia associated with antipsychotic medications / Fitzgerald, P.; Dinan, T.G. -- Impact of hyperprolactinaemia on the general health of patients with schizophrenia / Wildgust, H.J.; Kohen, D.
- 2009 ClinicalKeyeditor, J.K. Aronson.Antidepressants -- Neuroleptic Drugs -- Hypnosedatives -- Drugs of Abuse -- Drugs use in Alzheimer's Disease -- Psychological and Psychiatric Adverse Effects of Non-Psychoactive Drugs.
- 2013 SpringerCatherine Belzung, Peter Wigmore, editors.Neurogenesis in the Adult Mammalian Brain: How Much Do We Need, How Much Do We Have? / Ilias Kazanis -- Neurogenesis and Hippocampal Plasticity in Adult Brain / Yan Gu, Stephen Janoschka, Shaoyu Ge -- Adult-Born Neurons in the Olfactory Bulb: Integration and Functional Consequences / Gilles Gheusi, Gabriel Lepousez, Pierre-Marie Lledo -- Network, Cellular, and Molecular Mechanisms Underlying Long-Term Memory Formation / Mariana Carasatorre, Víctor Ramírez-Amaya -- Neurotrophins and Synaptic Plasticity / Andrea Gómez-Palacio-Schjetnan, Martha L. Escobar -- Differential Effects of Stress and Glucocorticoids on Adult Neurogenesis / Timothy J. Schoenfeld, Elizabeth Gould -- Effects of Environmental Enrichment Exposure on Synaptic Transmission and Plasticity in the Hippocampus / Michael J. Eckert, Wickliffe C. Abraham -- All About Running: Synaptic Plasticity, Growth Factors and Adult Hippocampal Neurogenesis / Carmen Vivar, Michelle C. Potter, Henriette van Praag -- The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory / Peter Wigmore -- Novel Insights into Depression and Antidepressants: A Synergy Between Synaptogenesis and Neurogenesis? / Francis Rodriguez Bambico, Catherine Belzung -- Deficient Plasticity in the Hippocampus and the Spiral of Addiction: Focus on Adult Neurogenesis / Juan J. Canales -- Prolonged Running, not Fluoxetine Treatment, Increases Neurogenesis, but does not Alter Neuropathology, in the 3xTg Mouse Model of Alzheimer's Disease / Michael W. Marlatt, Michelle C. Potter -- Hippocampal Neurogenesis and Ageing / Sébastien Couillard-Després -- Repair of the CNS Using Endogenous and Transplanted Neural Stem Cells / R. C. Trueman, A. Klein, H. S. Lindgren, M. J. Lelos.
- Neuropsychopharmacology : the fifth generation of progress : an official publication of the American College of Neuropsychopharmacology2002 Ovideditors, Kenneth L. Davis ... [et al.].Also available: Print – 2002
- 2015 WileyIvor S. Ebenezer.
- 2009 SpringerJack E. Henningfield, Edythe D. London, Sakire Pöğün, editors ; contributors, D.L. Ashley ... [et al.].Global patterns of nicotine and tobacco consumption / S.K. Hammond -- Nicotine chemistry, metabolism, kinetics and biomarkers / N.L. Benowitz, J. Hukkanen and P. Jacob, 3rd -- Nicotine content and delivery across tobacco products / M.V. Djordjevic and K.A. Doran -- The road to discovery of neuronal nicotinic cholinergic receptor subtypes / A.C. Collins ... [et al.] -- Magnetic resonance imaging studies of cigarette smoking / A. Azizian ... [et al.] -- In vivo brain imaging of human exposure to nicotine and tobacco / A. Sharma and A.L. Brody -- Molecular and cellular mechanisms of action of nicotine in the CNS / J. Barik and S. Wonnacott -- The neuronal pathways mediating the behavioral and addictive properties of nicotine / D.J. Balfour -- Molecular genetics of nicotine metabolism / J.C. Mwenifumbo and R.F. Tyndale -- Sex differences in nicotine action / S. Pogun and G. Yararbas -- Recognising nicotine: the neurobiological basis of nicotine discrimination / J.W. Smith and I.P. Stolerman -- Effects of nicotine in experimental animals and humans: an update on addictive properties / B. Le Foll and S.R. Goldberg -- Discriminative stimulus effects of nicotine in humans / K.A. Perkins -- Rodent models of nicotine withdrawal syndrome / D.H. Malin and P. Goyarzu -- Approaches, challenges, and experience in assessing free nicotine / D.L. Ashley ... [et al.] -- Tobacco industry manipulation of nicotine dosing / G.F. Wayne and C.M. Carpenter -- Pharmacotherapy for tobacco dependence / R.V. Fant ... [et al.] -- Nicotine psychopharmacology: policy and regulatory / J.E. Henningfield and M. Zeller.
- 2014 SpringerLaurence Claes, Jennifer J. Muehlenkamp, editors.Non-suicidal self-injury and eating disorders represent significant problems among today's youth and pose unique challenges for clinicians, particularly when they co-occur. This book is a rare resource in that it provides cutting-edge information on the interactions between self-injury and disordered eating, empirically informed treatments for the co-occurrence of these behaviors, and specific topics relevant to understanding nuances in the risk factors, treatment, and prevention of both self-injury and eating disorders. Practitioners, graduate students, and researchers working within this specialized area will find this text to be instrumental in advancing their knowledge and improving the treatment of self-injury in those with eating disorders.
- 2012 SpringerMark A. Geyer, Gerhard Gross, editors.This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
- 2012 Future Mededitor, Matcheri S. Keshavan.Pharmacological treatments in schizophrenia / Matcheri S. Keshavan -- Pathophysiology of psychotic disorders and the need for novel therapeutic targets / Matcheri S. Keshavan -- Current standard treatments / Joseph McEvoy -- Unmet medical needs in schizophrenia treatments / Mujeeb U. Shad -- Novel approaches for treating schizophrenia / Michael C. Davis & Stephen R. Marder -- Novel long-acting and extended-release formulations of antipsychotic drugs / Larry Alphs -- Future directions in the treatment of schizophrenia / Rajiv Tandon -- Index.
- 2011 SpringerDomenic A. Ciraulo, Richard Irwin Shader, editors.
- 2016 SpringerEdoardo Spina, Gianluca Trifirò, editors.1. Introduction: History of pharmacovigilance in psychiatry -- 2. Adverse drug reactions: definition and pathogenesis -- 3. Methodologies for pharmacovigilance monitoring of psychotropic drugs -- 4. The role of prescription event monitoring in pharmacovigilance of psychotropic drugs -- 5. The role of healthcare databases in pharmacovigilance of psychotropic drugs -- 6. Monitoring of plasma concentrations of psychotropic drugs in pharmacovigilance -- 7. The role of pharmacogenetics in pharmacovigilance of psychotropic drugs -- 8. Safety and tolerability of antidepressants -- 9. Safety and tolerability of antipsychotics -- 10. Safety and tolerability of anxiolytics/sedative hypnotics -- 11. Safety and tolerability of mood stabilizers -- 12. Safety and tolerability of medications for ADHD -- 13. Safety of psychotropic drugs in children and adolescents -- 14. Safety of psychotropic drugs in the elderly(Safety of psychotropic drugs in the elderly -- 15. Safety of psychotropic drugs in pregnancy and breastfeeding.
- 2016 SpringerTakashi Kudo, Kenneth L. Davis, Rafael Blesa Gonzalez, David George Wilkinson.Basic theory of pharmacology for Alzheimer's disease -- Practical Pharmacology of Donepezil -- Practical pharmacology of Galantamine -- Practical pharmacology of Rivastigmine -- Practical Pharmacology of Memantine -- How do we use Symptomatic drugs for Dementia.
- 2011 SpringerSrikanth Sajja, Ann M. Mortimer.Topics covered: Development of Psychotropic Drugs -- Research Methodology for Drug Trials -- Receptors -- Pharmacokinetics -- Pharmacodynamics -- Pharmacogenetics -- Anxiolytics, hypnotics -- Antipsychotic drugs -- Mood Stabilisers -- Antidepressant Drugs -- Antimuscarinic Drugs -- Antiepileptic Drugs -- Drugs Used in Movement Disorders -- Drugs Used in Substance Dependence -- Antidementia Drugs -- Adverse Reactions -- Drug Interactions -- Pharmacological Treatment of Psychiatric Disorders -- Psychopharmacology of Children -- Psychopharmocology of Elderly -- Psychopharmacology of Women -- Psychotropic Drugs in Special Patient Groups -- New Drugs -- Pharmacoeconomics -- Psycho Socio Cultural Aspects of Psychopharmacology.
- Practitioner's guide to prescribing antiepileptics and mood stabilizers for adults with intellectual disabilities2012 SpringerJose de Leon, editor.Emotional, behavioral, and neuropsychiatric conditions are common in individuals with intellectual disabilities (IDs), most notably epilepsy, aggression, self-injurious behaviors, and bipolar and other mood disorders. Despite the prevalence of such problems, there is a scarcity in the literature of reliable information on medical treatments for those with IDs. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities provides a detailed framework for prescribing for this challenging population. Featuring the most up-to-date information on factors that inform prescribing, the Guide addresses basic issues and controversies (e.g., the rift between evidence-based and personalized medicine) in treating adults with cognitive deficits. Clients' specific needs are emphasized in developing appropriate and effective pharmacological intervention for improved outcomes and quality of life. Drugs discussed in the Guide include carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lithium, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, Â tiagabine, topiramate, valproate, and zonisamide. For each of these compounds, the guidelines cover:Indications for use; relative and absolute contraindications. Assessment during treatment; therapeutic drug monitoring; warning signs and symptoms for caretakers. Dosage: administration; initial and maximum recommended dosage; modifications associated with drug-drug interactions, personal characteristics, and (where appropriate) genetic variations. Adverse drug reactions: common, relatively uncommon, and potentially lethal, plus risk of metabolic syndrome. Guidelines for discontinuation. References, tables, and drug utilization reviews. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities is an indispensable decision-making reference for psychiatrists, neuropsychologists, psychopharmacologists, neurologists, internists, and clinical psychologists.
- 2006 OvidPhilip G. Janicak ... [et al.].Pharmacodynamics and pharmacokinetics -- Assessment of drug efficacy and relevant clinical issues -- Indications for antipsychotics -- Treatment with antipsychotics -- Indications for antidepressants -- Treatment with antidepressants -- Treatment with electroconvulsive therapy and other device-based therapies -- Indications for mood stabilizers -- Treatment with mood stabilizers -- Indications for antianxiety and sedative-hypnotic agents -- Treatment with antianxiety and sedative-hypnotic agents -- Assessment and treatment of anxiety-related disorders -- Psychopharmacotherapy in early life -- Psychopharmacotherapy in later life -- Psychopharmacotherapy in special populations.
- 2011 OvidPhilip G. Janicak, Stephen R. Marder, Mani N. Pavuluri."Fully updated for its Fifth Edition, Principles and Practice of Psychopharmacotherapy summarizes the latest data on hundreds of drug and device-based therapies and offers practical, evidence-based guidelines and treatment strategies for virtually every psychiatric disorder. Highlights of this edition include expanded coverage of pharmacogenomics, updates on treatments for elderly patients, and discussion of mechanisms of action for drugs used in sleep disorders, especially narcolepsy"--Provided by publisher.
- 2014 SpringerManfred Gerlach, Andreas Warnke, Laurence Greenhill, editors.This book offers a comprehensive survey of the current state of knowledge in the field of neuro-psychopharmacology in childhood and adolescence. In the first part, the essentials of neuro-psychopharmacology are presented in order to provide a deeper understanding of the principles and particularities in the pharmacotherapy of children and adolescents. This part includes information on neurotransmitters and signal transduction pathways, molecular brain structures as targets for psychiatric drugs, characteristics of psychopharmacological therapy in children and adolescents, ontogenetic influences on pharmacokinetics and pharmacodynamics, and pharmacotherapy in the outpatient setting. The part on classes of psychiatric medications, which covers antidepressants, antipsychotics, anxiolytics and sedative-hypnotics, mood stabilizers, and psychostimulants and other drugs used in the treatment of attention-deficit/hyperactivity disorder, provides sufficient background material to better understand how psychoactive drugs work, and why, when, and for whom they should be used. For each drug within a class, information on its mechanisms of action, clinical pharmacology, indications, dosages, and cognate issues are reviewed. In the third part, the disorder-specific and symptom-oriented medication is described and discerningly evaluated from a practical point of view, providing physicians with precise instructions on how to proceed. Psychiatric Drugs in Children and Adolescents includes numerous tables, figures and illustrations and offers a valuable reference work for child and adolescent psychiatrists and psychotherapists, pediatricians, general practitioners, psychologists, and nursing staff, as well as teachers.
- 2006 Springeredited by Philip Gorwood, Michel Hamon.
- 2014 SpringerMegan Galbally, Martien Snellen, Andrew Lewis, editors.This book examines the role of psychopharmacological treatment in a range of disorders that may be encountered during pregnancy, including major depressive disorders, anxiety disorders, bipolar affective disorder, schizophrenia, eating disorders, and substance abuse. The natural history of each condition pre- and post-partum is analyzed, and the evidence for the efficacy of drug treatments, evaluated. Special attention is paid to the potential dangers of different treatment options for both mother and fetus, covering risks of malformation, pregnancy and obstetric risks, neonatal risks, and possible long-term consequences. The risks of not treating a particular condition are also analyzed. On the basis of the available evidence, management guidelines are provided that additionally take into account non-pharmacological options. Closing chapters consider the value of complementary and alternative medicine and ECT and explore future research directions.
- 2014 SpringerLuigi Grassi, Michelle Riba, editors.This practical manual presents the main drugs and protocols currently used in the psychopharmacological treatment of psychiatric disorders in cancer and palliative care settings and explores the principal issues involved in such treatment. Significant clinical challenges encountered in the psychopharmacological management of various psychiatric conditions are discussed, covering aspects such as side-effects and drug-drug interactions. Attention is also paid to the emerging theme of adjuvant use of psychotropic drugs for the treatment of symptoms or syndromes not primarily related to psychiatric disorders (e.g. pain, hot flashes). In addition, practical suggestions are provided for dealing with special populations, including children, the elderly, and people affected by severe mental illness. The book is designed to be easy to read and to reference: information is clearly displayed in concise tables and boxes, accompanied by further detail within the text and clinical vignettes. The authors include some of the most renowned clinicians working in the field of psycho-oncology.
- 1978 Kargervolume editor L. Valzelli.Also available: Print – 1978-
- 2014 SpringerPhillip G. Janicak, Stephen R. Marder, Rajiv Tandon, Morris Goldman, editors."Schizophrenia: Recent Advances in Diagnosis and Treatment is a major addition to the literature, offering practical, comprehensive coverage of diagnosis and treatment options, genetic issues, neuroimaging, long-term management of schizophrenia, and future directions and predictions of how clinical care of schizophrenia will change. The book is divided into five sections. Section 1 summarizes the present state of knowledge about the diagnosis and treatment of schizophrenia. This includes recent changes in the DSM 5 categorization of schizophrenia and its implications for treatment. Section 2 considers recent discoveries into its pathoetiology, including the status of biological markers, genetics and neuroimaging as they relate to diagnosis and potential novel therapeutic approaches. Section 3 explores the optimization of present therapeutic approaches; novel treatments; and management of the substantial risks associated with both the illness and its present therapies. Section 4 discusses progress in the long-term management of schizophrenia, focusing on biological and psychotherapeutic strategies to improve functioning and facilitate recovery. Section 5 considers future directions and predictions of how diagnosis and treatment of schizophrenia will change. An invaluable addition to the field, Schizophrenia: Recent Advances in Diagnosis and Treatment is a definitive resource that will be of great interest to all clinicians caring for patients with schizophrenia."--Publisher's website.
- 2012 SpringerCaio Maximino.Introduction -- Serotonin in the Nervous System of Vertebrates -- Nodal Structures in Anxiety-Like and Panic-Like Responses -- The Deakin-Graeff Hypothesis -- Topographic Organization of DRN -- General Conclusions.
- 2015 Springer Protocolsedited by Wolfgang Blenau, Universität zu Köln, Köln, Germany, Arnd Baumann, Forschungszentrum Jülich, Jülich, Germany.Novel Approaches to Serotonin Receptor Interaction Studies -- Techniques for the Study of GPCR Heteromerization in Living Cells and Animal Models -- Organotypic Slices and Biolistic Transfection for the Study of Serotonin Receptor Function in CNS Neurons -- Dissecting a Model of Depressive-Related Phenotype and Antidepressants Effects in 129S2/SvPas Mice -- The Murine Serotonin Syndrome and the 5-HT1A Receptor: Behavioral Effects and Hypothermia -- 5-HT4 Receptor Subtype, Î2-arrestin Level, and Rapid Onset Effects of Antidepressant Drugs -- Autoshaping Memory Formation and Retention Loss: Are Serotonin and Other Neurotransmitter Transporters Involved? -- Flow Cytometry to Determine Serotonin Transporter Function in Human Peripheral Blood Cells -- Functional Genomics of Serotonin Receptors in Helminth Parasites: Elucidation of Receptor Function through RNA Interference (RNAi) -- Visualization of the Serotonin System in Drosophila Brain: Immunofluorescence and Confocal Microscopy -- Serotonin Modulates Adult Neurogenesis in an Invertebrate Model: Approaches to Receptor Localization and Function -- Immunolocalization of Serotonergic Neurons in Arthropod Developmental and Phylogenetic Neuroanatomy.
- 2006 Springer[edited by] Malcolm Lader, Daniel P. Cardinali, S.R. Pandi-Perumal.GABA[subscript A] receptor subtypes in sedation and hypnosis / Esa R. Korpi -- Sleep hippocampal theta rhythm and sensory processing / Marisa Pedemonte and Ricardo A. Velluti -- Monoaminergic mechanisms in the regulation of sleep-wakefulness: special emphasis on preoptic noradrenergic system / Vijay Ramesh and Velayudhan Mohan Kumar -- REM sleep function and brain monoamine regulation: an application of the search activity concept / Vadim S. Rotenberg -- Role of wakefulness area in the brainstem reticular formation in regulating rapid eye movement sleep / Birendra N. Mallick ... [et al.] -- The mechanistic relationship between NREM sleep and anesthesia / Laura E. Nelson, Nicholas P. Franks, and Mervyn Maze -- Time-dependent psychotropic drug effects: hints of pharmacochronomics, broader than circadian time structures / Haruo Nagayama ... [et al.] -- Melatonin interaction with BZ-Gaba[subscript A] receptors: implications for sleep induction / Lennard P. Niles -- Melatonin: a chronobiotic that not only shifts rhythms / Dieter Kunz and Richard Mahlberg -- Melatonin and human sleep / Irina V. Zhdanova -- Melatonin efficacy to treat circadian alterations of sleep in Alzheimer's disease / Daniel P. Cardinali ... [et al.] -- Pharmacotherapy for seasonal affective disorder / Timo Partonen -- Use and discontinuation of hypnosedative medications / Mirko Petrovic -- Long-term use of sleeping pills in chronic insomnia / Milton Kramer -- Risks of chronic hypnotic use / Daniel F. Kripke -- Effects of psychotropics on driving performance / Henry J. Moller, Colin M. Shapiro, and Leonid Kayumov -- Diagnosis, pathophysiology and treatment of hypersomnias / Sebastiaan Overeem and Michel Billiard -- Chronic disease and sleep architecture pharmacotherapeutic considerations / James J. Herdegen -- Benzodiazepines for sedation in infants and children / Eugene Ng and Vibhuti Shah -- The pharmacological management of fatigue and sleepiness in affective disorders / Karl Doghramji -- Next-day residual effects of sleeping medications on driving ability: a review of the literature / Joris C. Verster, Marinus N. Verbaten, and Edmund R. Volkerts -- Sleep and pain / Wilfred R. Pigeon, Hyung Park, and Michael J. Sateia -- Head injuries and sleep / Chanth Seyone and Babita Kara -- Psychopharmacological management of restless legs syndrome and periodic limb movements in sleep / Raed Hawa ... [et al.] -- A comparison of visual analog scale and categorical ratings in assessing the patient's estimate of sleep quality / Nava Zisapel, Ricardo Tarrasch, and Moshe Laudon -- The pharmacostrategy of treating sleep disorders in Parkinsonism / Jean-Jacques Askenasy -- The neuropharmacology of nightmares / J.F. Pagel -- The night eating syndrome / Grethe Seta Birketvedt and Jon R. Florholmen -- Drug effects on dreaming / Mehmet Yucel Agargun and Hanefi Ozbek -- Sleep problems in primary care / Alan G. Wade -- SSRIs and sleep in man / Sue J. Wilson and David J. Nutt -- Sleep and antipsychotic drugs in schizophrenia patients / Jaime M. Monti and Daniel Monti -- Sleep and epilepsy: from interrelationships to influence of antiepileptic drugs / Antonio Martins da Silva ... [et all.] -- Herbal medicines and sleep / Marcello Spinella.
- 2005 Springeredited by W.E. Müller.
- 2009 PsychiatryOnlineedited by Alan F. Schatzberg and Charles B. Nemeroff.
- 2014 SpringerBeatriz Caiuby Labate, Clancy Cavnar, editors.This book presents a series of perspectives on the therapeutic potential of the ritual and clinical use of the Amazonian hallucinogenic brew ayahuasca in the treatment and management of various diseases and ailments, especially its role in psychological well-being and substance dependence. Biomedical and anthropological data on the use of ayahuasca for treating depression, PTSD, and substance dependence in different settings, such as indigenous contexts, neo-shamanic rituals, contemporary therapeutic circles, and in ayahuasca religions, in both South and North America, are presented and critiqued. Though multiple anecdotal reports on the therapeutic use of ayahuasca exist, there has been no systematic and dense reflection on the topic thus far. The book brings the therapeutic use of ayahuasca to a new level of public examination and academic debate. The texts in this volume stimulate discussion on methodological, ethical, and political aspects of research and will enhance the development of this emergent field of studies.
- 2016 SpringerTrevor W. Robbins, Barbara J. Sahakian, editors.
- Translational neuroscience : applications in psychiatry, neurology, and neurodevelopmental disorders2012 Cambridgeedited by James E. Barrett, Joseph T. Coyle, Michael Williams.A comprehensive and authoritative analysis of translational neuroscience, covering all major areas of psychiatry, neurology and neurodevelopmental disorders.
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Access restricted to Stanford community
Shortcut to Licensed Content
TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.
Bookmark on Other Websites
- TO INSTALL, RIGHT CLICK this button.
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
Can't find it?
Look if we have it in print
- Springer Protocols
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases
A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.
Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed Plus is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.
Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.
Includes cited reference searching, citation maps, and an analyze tool.
Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.
Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.
Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.
In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.
A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.
Over 10,000 notes outline the status of specific infections within each country.
Provides online, full-text access to Springer's journal titles as well as journals from other publishers.
Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.